ASSOCIATION OF C-ERBB2-GENE AMPLIFICATION WITH POOR-PROGNOSIS IN NONINFLAMMATORY BREAST CARCINOMAS BUT NOT IN CARCINOMAS OF THE INFLAMMATORY TYPE

S PROST, M G LE, S DOUCRASY, J C AHOMADEGBE, M SPIELMANN, M GUERIN, G RIOU

Research output: Contribution to journalArticlepeer-review

Abstract

It is now accepted that c-erbB2-gene amplification is correlated with poor clinical outcome for patients, mainly when axillary nodes are invaded. We have confirmed this result by multivariate analysis in 178 patients with non-inflammatory breast cancer followed up for a mean period of 6.8 years (SD, 1.6 years). In addition, we have shown that c-erbB2 amplification, found in 30 (17%) specimens, was associated with a high risk of multiple metastases developing simultaneously. In contrast, for the 67 patients with inflammatory breast carcinoma, the most aggressive type of breast carcinoma, the c-erbB2 amplification detected in 24 (36%) specimens was not found to be associated with a higher risk of death, suggesting that the c-erbB2 gene plays a different role in the progression of these 2 types of breast cancer. Furthermore, our data stress the importance of the methodological approach used to determine gene amplification. Although Southern blot hybridization is a tumour- and time-consuming method not easy to adopt in routine clinical practice, this method remains a reference quantitative method. (C) 1994 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)763-768
Number of pages6
JournalInternational Journal of Cancer
Volume58
Issue number6
Publication statusPublished - 15 Sep 1994

Keywords

  • PROTEIN OVEREXPRESSION
  • RECURRENT DISEASE
  • INCREASED RISK
  • FOLLOW-UP
  • CANCER
  • EXPRESSION
  • C-ERBB-2
  • ONCOGENE
  • PROLIFERATION
  • ONCOPROTEIN

Fingerprint

Dive into the research topics of 'ASSOCIATION OF C-ERBB2-GENE AMPLIFICATION WITH POOR-PROGNOSIS IN NONINFLAMMATORY BREAST CARCINOMAS BUT NOT IN CARCINOMAS OF THE INFLAMMATORY TYPE'. Together they form a unique fingerprint.

Cite this